The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Highlights from a Young Investigator Meeting session at iwCLL 2025
In this video, Moritz Fürstenau, MD, University Hospital of Cologne, Cologne, Germany, highlights the impressive quality of the clinical abstracts presented as part of a session in the Young Investigator Meeting (YIM) at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025. This interview took place at iwCLL 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I chaired a session in the Young Investigator meeting with the clinical abstracts and I was really impressed by the quality of the abstracts. And one abstract I really liked was a big cohort of patients treated in Poland here by the Polish Leukemia group with, I think, three to 400 patients treated with venetoclax and rituximab in the relapse setting and that’s almost twice the patient cohort size that was in the original MURANO study...
I chaired a session in the Young Investigator meeting with the clinical abstracts and I was really impressed by the quality of the abstracts. And one abstract I really liked was a big cohort of patients treated in Poland here by the Polish Leukemia group with, I think, three to 400 patients treated with venetoclax and rituximab in the relapse setting and that’s almost twice the patient cohort size that was in the original MURANO study. And this was just one poster abstract in the Young Investigators meeting, I think it could have been a big abstract in the main meeting. And there were other very interesting abstracts. For example, there was one abstract that I really enjoyed seeing by an investigator from Tanzania who rolled out a TP53 and IDH1 PCR assay at his hospital in Dar es Salaam in Tanzania, and showed that it was possible to also do these analyses reliably in a resource-poor setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
